Renal & Blood: Antiplatelet Drugs

Introduction/Overview

Platelet aggregation is a pivotal event in the pathogenesis of arterial thrombosis, a leading cause of myocardial infarction, ischemic stroke, and peripheral arterial disease. Antiplatelet agents constitute a cornerstone of primary and secondary prevention strategies, as well as adjunctive therapy in interventional cardiology. Their therapeutic value is particularly pronounced in patients with concomitant renal dysfunction, where altered pharmacokinetics and heightened bleeding risk necessitate careful selection and dosing. This chapter delineates the pharmacological landscape of antiplatelet drugs, emphasizing mechanisms of action, pharmacokinetic profiles, therapeutic indications, adverse effect spectra, drug interactions, and special considerations in renal and geriatric populations.

• Learning Objectives:
  1. Identify the major classes of antiplatelet agents and their chemical classifications.
  2. Explain the pharmacodynamic mechanisms underlying platelet inhibition.
  3. Describe key pharmacokinetic parameters influencing dosing and monitoring.
  4. Recognize therapeutic indications and off‑label applications.
  5. Assess adverse effects, drug interactions, and special patient considerations.

Classification

Chemical and Functional Categories

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Aspirin
  • Irreversible acetylation of cyclooxygenase‑1 (COX‑1).
  • Classified as an irreversible COX inhibitor.
• P2Y₁₂ Receptor Antagonists
  • Irreversible thienopyridines: ticlopidine, clopidogrel, prasugrel.
  • Reversible non‑thienopyridine: ticagrelor.
  • Intravenous reversible: cangrelor.
• Glycoprotein IIb/IIIa (GP IIb/IIIa) Inhibitors
  • Monoclonal antibodies: eptifibatide, tirofiban.
  • Small‑molecule agents: abciximab.
• Other Antiplatelet Agents
  • Cilostazol (phosphodiesterase‑3 inhibitor).
  • Dipyridamole (adenosine‑mediated inhibition).

Structural Features Relevant to Pharmacokinetics

• Aspirin – Small, lipophilic acetyl‑salicylic acid derivative. Rapid absorption in the stomach and proximal small intestine.
• Clopidogrel & Prasugrel – 3‑(3‑chlorophenyl)‑4‑hydroxy‑2‑(pyridin‑2‑yl)‑2‑(4‑pyridyl)‑1‑buten-3‑ol. Requires hepatic cytochrome P450 activation.
• Ticagrelor – 3‑(2‑(4‑pyridyl)‑4‑hydroxy‑2‑(3‑methyl‑pyridin‑2‑yl)‑4‑oxo‑2‑homo‑pyrrolidin‑1‑yl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑3‑oxo‑2‑homo‑pyrrolidin‑1‑yl‑3‑hydroxy‑2‑furan‑2‑yl‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)‑2‑(4‑pyridyl)…. (Complex, reversible binding).
• GP IIb/IIIa inhibitors – Peptide‑based or small‑molecule ligands that compete with fibrinogen binding sites.

Mechanism of Action

Aspirin

• Irreversibly acetylates serine 530 of COX‑1 in platelets, thereby inhibiting thromboxane A2 synthesis.
• Resultant reduction in platelet aggregation and prothrombotic signaling.
• Platelet inhibition persists for the lifespan of the platelet (≈7–10 days).

P2Y₁₂ Receptor Antagonists

• Irreversible thienopyridines (clopidogrel, prasugrel, ticlopidine) – Metabolized to active thiol derivatives that covalently bind to the P2Y₁₂ ADP receptor on platelets.
• Inhibition of ADP‑induced activation of the G_q pathway prevents phospholipase C activation and intracellular calcium mobilization.
• Consequence: Decreased ADP‑induced aggregation and integrin activation.
• Reversible agents (ticagrelor, cangrelor) – Bind non‑covalently to the allosteric site of the P2Y₁₂ receptor, allowing rapid reversibility upon drug discontinuation.
• Effect: Rapid onset of action, especially beneficial in acute coronary syndrome (ACS) settings.

GP IIb/IIIa Inhibitors

• Block the final common pathway of platelet aggregation by competitively inhibiting the binding of fibrinogen, von Willebrand factor, and other ligands to the GP IIb/IIIa receptor.
• Result: Prevention of platelet cross‑linking and thrombus stabilization.
• Administration is typically intravenous, with a short half‑life necessitating continuous infusion for sustained effect.

Cilostazol and Dipyridamole

• Cilostazol – Inhibits phosphodiesterase‑3, leading to increased cyclic AMP within platelets and vascular smooth‑muscle cells, thereby reducing platelet aggregation and inducing vasodilation.
• Dipyridamole – Enhances adenosine levels by inhibiting uptake and metabolism, promoting vasodilation and platelet inhibition via adenosine receptor activation.

Pharmacokinetics

Aspirin

• Absorption: Rapid, with peak plasma concentrations occurring 15–30 minutes after oral ingestion. Bioavailability ≈ 90–95% in healthy subjects.
• Distribution: Widely distributed; protein binding ≈ 40% to albumin.
• Metabolism: Hydrolyzed to salicylic acid, which is further conjugated to sulfate and glucuronide metabolites.
• Excretion: Renal elimination of metabolites; half‑life of salicylic acid ≈ 2–3 hours in adults.
• In patients with impaired renal function, accumulation of salicylate may occur, necessitating dose adjustment.

P2Y₁₂ Antagonists

Clopidogrel

• Absorption: Moderate; peak plasma concentration 1–2 hours post‑dose.
• Metabolism: Two‑step hepatic bioactivation via CYP2C19 and CYP3A4; only 10–15% of administered dose reaches the active metabolite.
• Distribution: Extensive, with plasma protein binding ≈ 99%. Half‑life of the active thiol metabolite ≈ 8 hours.
• Because of its irreversible platelet binding, the antiplatelet effect lasts for the lifespan of the platelet.

Prasugrel

• Metabolically activated by CYP3A4 and CYP2B6, achieving higher platelet inhibition than clopidogrel.
• Rapid absorption; peak effect within 2–4 hours.
• Half‑life of active metabolite ≈ 7–8 hours.

Ticagrelor

• Rapid absorption; peak plasma concentration within 1 hour.
• Metabolized by CYP3A4 to an active metabolite (AR-C124910XX) with similar activity.
• Half‑life of ticagrelor ≈ 8 hours; active metabolite ≈ 12.5 hours.
• Reversible binding allows platelet function to recover within 6–8 hours after discontinuation.

Cangrelor

• Intravenous administration; peak effect within minutes.
• Half‑life ≈ 3–5 minutes; eliminated primarily by rapid redistribution and renal excretion.
• Ideal for periprocedural antiplatelet coverage.

GP IIb/IIIa Inhibitors

• Eptifibatide – Rapid onset (4–5 minutes) with a half‑life of 2–3 hours. Renally cleared; dose adjustment required in chronic kidney disease.
• Tirofiban – Similar pharmacokinetics; half‑life ≈ 2–3 hours.
• Abciximab – Longer half‑life (≈ 8–12 hours); primarily eliminated via receptor‑mediated clearance.

Cilostazol and Dipyridamole

• Cilostazol – Oral bioavailability ≈ 15%; metabolized by CYP3A4 and CYP2C19. Half‑life ≈ 11 hours.
• Dipyridamole – Rapid absorption; half‑life ≈ 2–3 hours. Renal excretion of metabolites; dose adjustment recommended in renal impairment.

Therapeutic Uses / Clinical Applications

Primary and Secondary Prevention of Cardiovascular Events

• Aspirin – Low‑dose (75–150 mg/day) for primary prevention in patients with elevated cardiovascular risk; standard-dose (300–325 mg/day) for secondary prevention post‑myocardial infarction or revascularization.
• P2Y₁₂ Antagonists – Dual antiplatelet therapy (DAPT) with aspirin for 12 months post‑percutaneous coronary intervention (PCI) with stent placement; longer duration in complex coronary disease.
• GP IIb/IIIa Inhibitors – Short‑term adjunctive therapy during PCI, particularly in high thrombotic burden or bailout situations.
• Cilostazol – Preferred for intermittent claudication in patients intolerant to aspirin or with contraindications to NSAIDs.
• Dipyridamole – Combined with aspirin for secondary stroke prevention; also used in atrial fibrillation when anticoagulation is contraindicated.

Off‑Label and Emerging Applications

• Ticagrelor – Investigated for acute ischemic stroke management and in patients with high platelet reactivity despite clopidogrel therapy.
• Clopidogrel, Prasugrel, Ticagrelor – Utilized in extracorporeal circulation (hemodialysis) to mitigate platelet activation.
• GP IIb/IIIa Inhibitors – Employed in acute coronary syndrome with high thrombotic risk and in patients undergoing complex coronary interventions.
• Cilostazol – Explored for microcirculatory disorders, such as Raynaud phenomenon and peripheral artery disease.

Adverse Effects

Common Side Effects

• Aspirin – Gastrointestinal discomfort, dyspepsia, epigastric pain. Bleeding tendency, especially upper GI bleeding.
• Clopidogrel, Prasugrel, Ticagrelor – Bleeding (cutaneous, mucosal, intracranial), dyspnea (ticagrelor), and, rarely, thrombocytopenia.
• GP IIb/IIIa Inhibitors – Bleeding, thrombocytopenia, hypotension, bradycardia (tirofiban).
• Cilostazol – Headache, palpitations, tachycardia, edema.
• Dipyridamole – Headache, dizziness, flushing.

Serious and Rare Reactions

• Aspirin – Aspirin‑induced asthma, hypersensitivity reactions, Reye syndrome in children.
• Clopidogrel, Prasugrel – Severe allergic reactions, drug‑related thrombocytopenia.
• Ticagrelor – Pulmonary hypertension, sudden dyspnea; reversible platelet inhibition may lead to paradoxical platelet activation upon abrupt cessation.
• GP IIb/IIIa Inhibitors – Severe thrombocytopenia, immune‑mediated reactions, myocardial infarction due to paradoxical clot formation.

Black Box Warnings

• All antiplatelet agents carry a boxed warning for bleeding risk, including gastrointestinal, intracranial, and hemorrhagic stroke.
• Specific warnings for ticagrelor regarding dyspnea and for clopidogrel regarding hypersensitivity reactions.

Drug Interactions

Major Drug–Drug Interactions

• Aspirin – Concomitant NSAIDs may reduce antiplatelet effect due to competitive COX inhibition; anticoagulants (warfarin, DOACs) increase bleeding risk.
• Clopidogrel – CYP2C19 inhibitors (e.g., proton pump inhibitors such as omeprazole) reduce activation; CYP3A4 inducers (e.g., rifampin) decrease efficacy.
• Prasugrel – Similar CYP interactions; caution with CYP3A4 inducers.
• Ticagrelor – CYP3A4 inhibitors (ketoconazole) increase plasma levels; CYP3A4 inducers (carbamazepine) decrease efficacy.
• GP IIb/IIIa Inhibitors – Concomitant anticoagulants increase bleeding; antiplatelet synergy may be beneficial in high‑risk PCI.
• Cilostazol – CYP3A4 inhibitors (ketoconazole) elevate serum levels; MAO inhibitors may increase bleeding.
• Dipyridamole – CYP2C19 inhibitors reduce metabolism; concomitant anticoagulants amplify bleeding risk.

Contraindications

• History of hypersensitivity to the drug or any component.
• Active major bleeding or recent significant hemorrhagic stroke.
• Uncontrolled hypertension (particularly with GP IIb/IIIa inhibitors).
• Concurrent use of certain anticoagulants without careful monitoring.

Special Considerations

Renal Impairment

• Aspirin – Metabolite accumulation may cause salicylate toxicity; dose reduction or intermittent dosing may be required.
• Clopidogrel, Prasugrel – Renal clearance not a major pathway; however, uremic platelet dysfunction may influence efficacy.
• Ticagrelor – Renal elimination of metabolites; dose adjustment recommended for eGFR <30 mL/min.
• GP IIb/IIIa Inhibitors – Eptifibatide and tirofiban require dose adjustment in patients with eGFR <30 mL/min; abciximab less affected.
• Cilostazol – Metabolism via hepatic CYP3A4; renal impairment may prolong half‑life; dose reduction advised.
• Dipyridamole – Metabolite excretion via kidneys; dose adjustment needed in severe renal disease.

Hepatic Impairment

• Clopidogrel, prasugrel, ticagrelor, and cilostazol are metabolized by hepatic CYP enzymes; significant hepatic dysfunction may reduce activation and efficacy.
• Monitoring of liver function tests is recommended when initiating therapy.

Pediatrics

• Aspirin is used for Kawasaki disease and viral illnesses but is contraindicated in viral infections due to Reye syndrome.
• Clopidogrel and prasugrel lack sufficient pediatric data; ticagrelor has limited use in children.
• GP IIb/IIIa inhibitors are generally avoided in pediatric populations.

Pregnancy and Lactation

• Aspirin is considered category B; low‑dose therapy may be used in preeclampsia prevention but higher doses are avoided.
• Clopidogrel and ticagrelor are category C; use only if benefits outweigh risks.
• GP IIb/IIIa inhibitors are generally contraindicated in pregnancy due to bleeding risk.
• Cilostazol and dipyridamole have insufficient data; prudent avoidance is recommended.

Geriatric Population

• Increased sensitivity to bleeding; careful titration and monitoring are essential.
• Renal and hepatic function decline with age; dose adjustments may be necessary.
• Polypharmacy increases interaction risk; comprehensive medication review advised.

Summary / Key Points

• Aspirin remains the foundational antiplatelet agent for both primary and secondary prevention, operating via irreversible COX‑1 inhibition.
• P2Y₁₂ antagonists provide potent platelet inhibition, with reversible agents offering rapid onset and offset desirable in acute coronary syndromes.
• GP IIb/IIIa inhibitors serve as short‑term adjuncts during high‑risk percutaneous coronary interventions, with careful attention to bleeding risk.
• Renal and hepatic function significantly influence pharmacokinetics; dose adjustments and monitoring are imperative in impaired organ function.
• Drug–drug interactions, particularly involving CYP enzymes, can markedly alter antiplatelet efficacy and safety; vigilant assessment of concomitant medications is required.
• Special populations—including pregnant women, children, elderly, and patients with renal or hepatic impairment—necessitate individualized therapeutic strategies and close surveillance for adverse events.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.